NeurAxis, Inc. (NRXS)
NeurAxis, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Carmel, IN, US. The stock last traded at $6.40, up 0.79% on the session, giving a market capitalisation of $79.9M. On trailing twelve-month figures it carries a trailing P/E of -8.31, a net margin of -148.0%. Its beta of 1.47 implies it has historically moved more than the broad market.
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
NeurAxis, Inc. is most often compared with the following Healthcare names: